Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1411-1417

  Wong, Gloria ^a   Farkas, Andras ^b,c   Sussman, Rachel ^d   Daroczi, Gergely ^e   Hope, William W ^f   Lipman, Jeffrey ^a,g   Roberts, Jason A ^a,f,g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Vassar Brothers Medical Center   (United States)

^c Optimum Dosing Strategies   (United States)

^d ST BARNABAS HOSPITAL   (United States)

^e EasyStats LTD   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACCURACY; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE (PEOPLE); KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; ADULT; BIOLOGICAL MODEL; CRITICAL ILLNESS; DRUG MONITORING; MIDDLE AGED;

ADULT; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG MONITORING; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; THIENAMYCINS;

EID: 84923218989     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04001-14     Document Type: Article

References (25)

1. Roberts JA, Abdul Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. 2014. Challenges and potential solutions-individualized antibiotic dosing at the bedside for critically Ill patients: a structured review. Lancet Infect Dis 14:498-509. http://dx.doi.org/10.1016/S1473-3099(14)70036-2.
2. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J. 2014. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072-1083. http://dx.doi.org/10.1093/cid/ciu027.
3. Roberts JA, Kruger P, Paterson DL, Lipman J. 2008. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 36:2433-2440. http://dx.doi.org/10.1097/CCM.0b013e318180fe62.
4. Craig WA. 1997. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 24:S266-S275. http://dx.doi.org/10.1093/clinids/24.Supplement-2.S266.
5. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. 2004. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 26:1187-1198. http://dx.doi.org/10.1016/S0149-2918(04)80001-8.
6. Li C, Du X, Kuti JL, Nicolau DP. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725-1730. http://dx.doi.org/10.1128/AAC.00294-06.
7. Li C, Kuti JL, Nightingale CH, Nicolau DP. 2006. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171-1178. http://dx.doi.org/10.1177/0091270006291035.
8. Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim DS. 2010. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 65:2428-2435. http://dx.doi.org/10.1093/jac/dkq317.
9. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. 2011. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 37:632-638. http://dx.doi.org/10.1007/s00134-010-2105-0.
10. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. 2009. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142-150. http://dx.doi.org/10.1093/jac/dkp139.
11. Leroy A, Fillastre JP, Etienne I, Borsa-Lebás F, Humbert G. 1992. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 42:535-538. http://dx.doi.org/10.1007/BF00314864.
12. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Öqvist B, Norrby SR. 1992. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 36: 1532-1537. http://dx.doi.org/10.1128/AAC.36.7.1532.
13. Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. 1992. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 36:2794-2798. http://dx.doi.org/10.1128/AAC.36.12.2794.
14. Muro T, Sasaki T, Hosaka N, Umeda Y, Takemoto S, Yamamoto H, Kamimura H, Higuchi S, Karube Y. 2011. Population pharmacokinetic analysis of meropenem in Japanese adult patients. J Clin Pharm Ther 36:230-236. http://dx.doi.org/10.1111/j.1365-2710.2010.01171.x.
15. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
16. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. 2010. Analysis of twelve beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 878:2039-2043. http://dx.doi.org/10.1016/j.jchromb.2010.05.027.
17. Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JP. 2012. A method for determining the free (unbound) concentration of ten betalactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 907:178-184. http://dx.doi.org/10.1016/j.jchromb.2012.09.016.
18. Astra Zeneca. 2013. Merrem (meropenem) package insert. Astra Zeneca, Wilmington, DE.
19. Bland JM, Altman DG. 2003. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 22:85-93. http://dx.doi.org/10.1002/uog.122.
20. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512. http://dx.doi.org/10.1007/BF01060893.
21. Gabrielsson J, Weiner D. 2000. Modeling strategies, p 261-326. In PK/PD data analysis: concepts and applications, 3rd ed, Swedish Pharmaceutical Press, Stockholm, Sweden.
22. Baldwin CM, Lyseng-Williamson KA, Keam SJ. 2008. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 68:803-838. http://dx.doi.org/10.2165/00003495-200868060-00006.
23. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. 2010. Therapeutic drug monitoring of betalactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332-339. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.008.
24. Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, Louie A. 2011. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 12:2044-2061. http://dx.doi.org/10.2174/138920111798808428.
25. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA. 2013. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165-6170. http://dx.doi.org/10.1128/AAC.00951-13.